RedHill Biopharma Ltd. announced that its partner, Gaelan Medical LLC has received marketing approval from the United Arab Emirates (UAE) Ministry of Health for Talicia (omeprazole magnesium, amoxicillin and rifabutin). The approval makes Talicia the first approved rifabutin-containing all-in-one combination product in the UAE specifically designed to treat H. pylori. Clarithromycin-based triple therapy continues to wane in effectiveness. A 2021 study demonstrated only 68.5% eradication with traditional clarithromycin-based triple therapy, which declined further to 32% in patients harboring resistant H. pylori organisms. Other studies have also shown that for clarithromycin-resistant strains of H. pylori the risk of eradication failure increases 3-7?fold when treated with clarithromycin-containing regimens.

Clarithromycin-based treatment efficacy can also be negatively impacted by patient BMI or diabetic status, neither of which impact Talicia's eradication rates, according to data from post-approval post-hoc analysis.